ArticleEndocrine2021
Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.Scientific reports · 2025Article
- Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.Acta neurochirurgica · 2024Article
- Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight.BMC endocrine disorders · 2024Article
- Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.Frontiers in endocrinology · 2024Article
- [Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma].Problemy endokrinologii · 2023Observational
- Prolactinomas in adolescent and elderly patients-A comparative long-term analysis.Frontiers in surgery · 2023Article
- Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.Frontiers in endocrinology · 2022Article
- First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.Journal of endocrinological investigation · 2021Article
- Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.Scientific reports · 2021Article
- Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.Journal of clinical & translational endocrinology · 2021Article
- Commentary: "Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery".Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCabergoline (CAB) therapy for prolactinomas has been associated with serum IGF-1 levels modifications, with recent reports indicating a paradoxical increase of IGF-1 levels during ongoing therapy. As a result, IGF-1 measurement has been proposed not only at diagnosis of a prolactinoma, but also during follow-up. In this follow-up study on prolactinoma patients with chronic CAB therapy, we investigated whether there are long-term changes in IGF-1 levels that necessitate continuous monitoring.
methodsWe reviewed our institutional database on prolactinoma patients with long-term CAB therapy, in whom IGF-1 levels were measured at baseline, at 3-months follow-up and in the long term.
resultsChronic CAB therapy was noted in 20 patients (13 men, 7 women). Median (±SD) age was 43.5 ± 12.6 years. 17 (85%) patients presented with a macroprolactinoma. Median CAB treatment time was 75 ± 43 months (range 24-187). Median IGF-1 levels increased at last follow-up, though not significantly; from 122 ± 37 ng/ml (IQR 104-160 ng/ml) to 133 ± 54 (IQR 121-162 ng/ml), p = 0.10. Thereby, 18 (90%) patients showed normal serum IGF-1 levels adjusted for age, one (5%) patient above (1.05 × ULN) and 1 (5%) patient below the normal range (0.34 × ULN). No patient was or became symptomatic of acromegaly.
conclusionOur long-term results indicate that chronic treatment with CAB in prolactinoma patients does not significantly modify serum IGF-1 levels. Bearing in mind the sample size of this study, continuing IGF-1 monitoring is not indicated in prolactinoma patients with long-term CAB therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.